A team of scientists has made valuable progress toward creating clinical-grade cells for treatment of bone disease and injury. In their study, the team identified two types of growth media that could support effective expansion of mesenchymal progenitor (MP) cells from stem cells in a clinically compatible, Good Manufacturing Practice (GMP) setting.
